Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent

NCT02660047 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus Type 2
Metabolic Syndrome
Cardiovascular Disease
Diastolic Dysfunction
Fatty Liver

Interventions

DRUG: Liraglutide
DRUG: Liraglutide - Placebo

Sponsor

Leiden University Medical Center

Collaborators

[object Object]